Searched for
INDIA PANACEA BIOTEC
Dispute with Sanofi settled, Panacea scrip soars to over 3-yr highPanacea Biotec has settled a patent dispute with Sanofi Healthcare India, leading to a rise in its stock. The Delhi High Court case involve...- Panacea, Sanofi settle patent litigation over hexavalent vaccinePanacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Sh...
- DFC commits USD 20 mn long-term loan to Panacea BiotecUS International Development Finance Corporation has committed a long-term loan of up to USD 20 million to Panacea Biotec. The funds will h...
- Panacea Biotec hits 5% upper circuit after Mankind Pharma dealAs part of this arrangement, Mankind Pharma is retaining Panacea's sales and marketing team engaged in the particular business.
- Mankind Pharma to acquire Panacea's formulation brands for India, NepalBoth the entities have entered into definitive agreements for the transaction involving a total consideration of Rs 1,872 crore. Panacea Bi...
- Panacea arm defaults; lenders may extend repayment datePanacea Biotec Pharma, a 100% subsidiary of Sputnik V Covid jab manufacturer Panacea Biotec, defaulted on payment of ₹114.67 crore includin...
- Panacea Biotec supplies second component of Sputnik V vaccine in IndiaThe second component of Sputnik V has been manufactured at the company's vaccine manufacturing facility in Himachal Pradesh, Panacea Biotec...
- Panacea Biotec soars 5% as production of Sputnik V kicks offShares of Panacea Biotec have delivered 190 per cent return in the last one year, soaring from Rs 141.5 to Rs 407.2. The counter has more t...
- Adar Poonawalla transfers entire Panacea Biotec stake worth Rs 118 cr to Serum InstitutePoonawalla sold 3.15 million shares of Panacea Biotech at Rs 373.85 per share to Serum Institute in a block deal on the BSE earlier today.
- Panacea Biotec files suit against Sanofi for patent infringement"The suit filed against Sanofi comes at the heels of Sanofi having received marketing approval for a Whole Cell Pertussis based Hexavalent ...
- Panacea Biotec soars 17% after company signs deal to produce Sputnik V vaccine dosesProduction of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF, a joint ...
- RDIF, Panacea Biotec to produce 100 million doses of Sputnik V vaccine in India per yearIndian biotech firm Panacea Biotec Ltd has agreed to produce 100 million doses of Russia's Sputnik V COVID-19 vaccine annually.
- Panacea Biotec partners Serum Institute for hexavalent vaccineThe vaccine is a combination of six antigens to protect against six dreaded diseases - Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemoph...
- Panacea Biotec launches diabetes drug 'Tenepan'Tenapan aims to improve accessibility of diabetes treatment at an affordable cost as part of the company's commitment to the 'Make in India...
- Panacea launches prostate cancer drugDrug firm Panacea Biotec today launched Cabapan injection, an indigenously developed drug for treating prostate cancer.
- Panacea Biotec Q3 net loss at Rs 62.28 crorePharma firm Panacea Biotec today reported net loss of 62.28 crore for the third quarter ended December 31, 2012.
- Serum Institute buys 3 lakh shares of Panacea for Rs 3.7 crVaccine firm Serum Institute of India today purchased about three lakh shares of Panacea Biotec for Rs 3.71 crore through open market trans...
- Serum Institute hikes stake in Panacea Biotec to 7%India’s largest vaccine maker, Serum Institute of India, has picked up close to 7% stake in rival firm Panacea Biotec.
- Panacea enters into alliance with US-based PharmAtheneVaccine manufacturer Panacea Biotec on Wednesday said it has entered into a strategic alliance with US-based PharmAthene and will invest 13...
- Panacea bags $35-m deal from UnicefPanacea Biotec is learnt to have bagged a $35-million drug supply order from UNICEF to supply pentavalent vaccines, the first Indian compan...
Load More
